Inclusion Criteria:

- Males and females 18 years of age or older.

- Subjects must have started Tarceva® therapy within three (3) days of trial
enrollment.

- Patients must have signed informed consent prior to registration on study.

- Currently receiving erlotinib therapy at 150 mg per day for locally advanced or
metastatic NSCLC.

- Patients - both males and females - with reproductive potential (ie, menopausal for
less than 1 year and not surgically sterilized) must utilize barrier methods in
combination with spermicidal agents for contraception when engaging in sexual
intercourse. Women of childbearing potential must provide a negative pregnancy test
(serum or urine) within 14 days prior to registration.

Exclusion Criteria:

- Allergy to tetracyclines.

- Use of concurrent agents for papulopustular rash.

- Currently receiving anticancer agents other than erlotinib.

- Inability to interrupt other antibiotic therapy.

- Current use of topical steroids

- Current use of systemic immunosuppressants (e.g., methotrexate, cyclosporine,
azathioprine, mycophenolate mofetil)

- Photosensitivity or lupus erythematosus.

- Active gastroesophageal reflux disease.

- Women who have a positive pregnancy test or are lactating by history.

- ECOG performance status ≤3.

- Self report of current smoking or history of smoking within 60 days of screening, or
positive urine cotinine test.

- Current use of agents that are known to be strong inducers or inhibitors of CYTP3A4:

- inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,
nefazodone, nelfi navir, ritonavir, saquinavir, telithromycin, troleandomycin
(TAO), voriconazole, grapefruit or grapefruit juice

- inducers: rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine,
phenobarbital, and St. John's Wort

- Impaired hepatic function (≤ 30 days before randomization):

- Alkaline phosphatase > 3x ULN

- Aspartate aminotransferase (AST) > x ULN

- Alanine aminotransferase (ALT) > 3 x ULN

- Total Bilirubin > 1.5 x ULN